2seventy bio, Inc. (TSVT)
After hours:
- Business Wire
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
PRINCETON, N.J., & CAMBRIDGE, Mass., April 05, 2024--U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma
- Business Wire
2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
CAMBRIDGE, Mass., April 01, 2024--2seventy bio, Inc. (Nasdaq: TSVT), announced today the completion of the asset purchase agreement ("APA") by Regeneron Pharmaceuticals, Inc. Under the terms of the APA, Regeneron has acquired all oncology and autoimmune research and development programs and has hired approximately 160 employees from 2seventy bio as part of their newly launched cell medicines business. Going forward, 2seventy bio will focus exclusively on the commercialization and development of
- Business Wire
2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
CAMBRIDGE, Mass., March 20, 2024--2seventy bio, Inc. (Nasdaq: TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company’s Board of Directors (the "Board"), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio’s outstanding shares as of 03/20/24.
